| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6436989 | VIIV HLTHCARE | Prodrugs of aspartyl protease inhibitors |
Dec, 2017
(6 years ago) | |
|
US6436989 (Pediatric) | VIIV HLTHCARE | Prodrugs of aspartyl protease inhibitors |
Jun, 2018
(5 years ago) | |
| US6514953 | VIIV HLTHCARE | Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate |
Jul, 2019
(4 years ago) | |
|
US6514953 (Pediatric) | VIIV HLTHCARE | Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate |
Jan, 2020
(4 years ago) | |
Lexiva is owned by Viiv Hlthcare.
Lexiva contains Fosamprenavir Calcium.
Lexiva has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Lexiva are:
- US6436989
- US6436989*PED
- US6514953
- US6514953*PED
Lexiva was authorised for market use on 20 October, 2003.
Lexiva is available in tablet;oral, suspension;oral dosage forms.
Lexiva can be used as treatment of hiv infection.
The generics of Lexiva are possible to be released after 15 January, 2020.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Oct 27, 2015 |
| New Patient Population(NPP) | Apr 27, 2015 |
Drugs and Companies using FOSAMPRENAVIR CALCIUM ingredient
Market Authorisation Date: 20 October, 2003
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL; SUSPENSION;ORAL
How can I launch a generic of LEXIVA before it's drug patent expiration?
More Information on Dosage
LEXIVA family patents
